Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Gastroenterology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.Aliment Pharmacol Ther. 2011; 34: 274-285
- NAFLD in Asia—as common and important as in the west.Nat Rev Gastroenterol Hepatol. 2013; 10: 307-318
- Non-alcoholic fatty liver disease in diabetics–prevalence and predictive factors in a multiracial hospital clinic population in Malaysia.J Gastroenterol Hepatol. 2013; 28: 1375-1383
- Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III).Am J Med Sci. 2005; 329: 111-116
- Prevalence of fatty liver in children and adolescents.Pediatrics. 2006; 118: 1388-1393
- The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years.Gut. 2009; 58: 1538-1544
- Long-term follow-up of patients with nonalcoholic fatty liver.Clin Gastroenterol Hepatol. 2009; 7: 234-238
- Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.J Hepatol. 2012; 56: 1384-1391
- Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatology. 2006; 44: 865-873
- Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).Dig Dis Sci. 2013; 58: 3017-3023
- Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.Gastroenterology. 2015; 148: 547-555
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013.Lancet. 2014; 384: 766-781
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology. 2015; 61: 1547-1554
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.J Hepatol. 2015; 62: 1148-1155
- Protein nutrition and liver disease after jejunoileal bypass for morbid obesity.N Engl J Med. 1974; 290: 921-926
- Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc. 1980; 55: 434-438
- Fatty liver hepatitis and cirrhosis in obese patients.Am J Med. 1979; 67: 811-816
- Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.Hepatology. 1990; 12: 1106-1110
- The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.Hepatology. 1990; 11: 74-80
- The natural history of nonalcoholic fatty liver: a follow-up study.Hepatology. 1995; 22: 1714-1719
- Final results of a long-term, clinical follow-up in fatty liver patients.Scand J Gastroenterol. 2009; 44: 1236-1243
- Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol. 2015; 13: 643-654
- Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.Gastroenterology. 1999; 116: 1413-1419
- Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.Scand J Gastroenterol. 2012; 47: 108-115
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.J Hepatol. 2013; 59: 550-556
- Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.Gut. 2010; 59: 969-974
- Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.J Hepatol. 2009; 51: 371-379
- Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.Am J Gastroenterol. 1999; 94: 2467-2474
- The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.Am J Gastroenterol. 2003; 98: 2042-2047
- Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.Liver Int. 2009; 29: 1431-1438
- Silent non-alcoholic fatty liver disease—a clinical-histological study.J Hepatol. 2004; 41: 751-757
- In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.Metab Clin Exp. 2013; 62: 352-360
- Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology. 2015; 149: 389-397
- The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology. 2005; 129: 113-121
- Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.Hepatology. 2003; 37: 1286-1292
- Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.Hepatology. 2011; 53: 1874-1882
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the united states.Hepatology. 2013; 57: 1357-1365
- Sampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology. 2005; 128: 1898-1906
- Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability.Aliment Pharmacol Ther. 2007; 26: 821-830
- Adipokines and cytokines in non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2008; 27: 412-421
- Metabolic and adipokine profile of chinese patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2006; 4: 1154-1161
- Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance.Obes Surg. 2006; 16: 1118-1125
- Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.Hepatology. 2005; 42: 1175-1183
- Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study.J Clin Gastroenterol. 2005; 39: 237-242
- Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.Clin Endocrinol (Oxf). 2006; 64: 679-683
- Beyond insulin resistance in NASH: TNF-α or adiponectin?.Hepatology. 2004; 40: 46-54
- Detection of elevated caspase activation and early apoptosis in liver diseases.Eur J Cell Biol. 2001; 80: 230-239
- Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.Hepatology. 2012; 55: 455-464
- Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.Hepatology. 2009; 50: 1072-1078
- In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.Hepatology. 2006; 44: 27-33
- Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.J Dig Dis. 2011; 12: 10-16
- Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.Eur J Gastroenterol Hepatol. 2011; 23: 499-506
- Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol. 2006; 6: 34
- Adipokines and insulin resistance.Mol Med. 2008; 14: 741-751
- A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).Obes Surg. 2008; 18: 1430-1437
- A “biomarker biopsy” for the diagnosis of NASH: promises from CK-18 fragments.Obes Surg. 2008; 18: 1507-1508
- A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.Obes Surg. 2011; 21: 431-439
- Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.Liver Int. 2006; 26: 151-156
- Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.Am J Gastroenterol. 2007; 102: 1931-1938
- A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients.Aliment Pharmacol Ther. 2010; 32: 1315-1322
- The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology. 2007; 45: 846-854
- The utility of the “NAFLD fibrosis score” in morbidly obese subjects with NAFLD.Obes Surg. 2008; 18: 264-270
- Comparison of blood tests for liver fibrosis specific or not to NAFLD.J Hepatol. 2009; 50: 165-173
- Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.Am J Gastroenterol. 2008; 103: 1682-1688
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology. 2006; 43: 1317-1325
- Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2009; 7: 1104-1112
- Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.J Clin Pathol. 2013; 66: 1033-1045
- Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology. 2013; 145: 782-789
- Serum markers detect the presence of liver fibrosis: a cohort study.Gastroenterology. 2004; 127: 1704-1713
- Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers.Hepatology. 2008; 47: 455-460
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut. 2008; 57: 1441-1447
- Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut. 2010; 59: 1265-1269
- Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.Hepatology. 2018; 67: 1348-1359
- Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2019; 17: 156-163.e2
- Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.J Hepatol. 2017; 66: 1022-1030
- Controlled attenuation parameter for the detection and quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.United Eur Gastroenterol J. 2017; 5: 76-85
- Controlled attenuation parameter (CAP) with the XL probe of the fibroscan. A comparative study with the M probe and liver biopsy.Dig Dis Sci. 2017; 62: 2569-2577
- Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography.Gastroenterology. 2016; 150: 626-637.e7
- Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease.Gastroenterology. 2017; 152: 598-607.e2
- MR spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis.Radiology. 2018; 286: 547-556
- Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.Ultrasound Med Biol. 2003; 29: 1705-1713
- Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.Hepatology. 2010; 51: 454-462
- Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations.Hepatology. 2010; 51: 828-835
- Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease the role of transient elastography and plasma cytokeratin-18 fragments.Aliment Pharmacol Ther. 2014; 39: 254-269
- Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis.Hepatology. 2017; 66: 1486-1501
- The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease.Am J Gastroenterol. 2016; 111: 677-684
- Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD.Aliment Pharmacol Ther. 2017; 46: 617-627
- Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis.PLoS One. 2015; 10: e0127782
- Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis.Hepatology. 2018; 67: 260-272
- EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.J Hepatol. 2015; 63: 237-264
- Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.Hepatology. 2013; 58: 1930-1940
- Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease–MRI accurately quantifies hepatic steatosis in NAFLD.Aliment Pharmacol Ther. 2012; 36: 22-29
- Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.Radiology. 2011; 259: 749-756
- Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study.Am J Gastroenterol. 2016; 111: 986-994
- Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study.Hepatology. 2016; 63: 453-461
- Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study.Hepatology. 2014; 60: 1920-1928
- The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery.Hepatology. 2018; ([Epub ahead of print])
- Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.Liver Int. 2017; 37: 1065-1073
- Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.Gastroenterology. 2019; 156: 1264-1281
- The combination of liver stiffness measurement and NAFLD Fibrosis Score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.Liver Int. 2015; 35: 1566-1573
- MRI and MRE for non-invasive quantitative assessment of hepatic steatosis in NAFLD and NASH: clinical trials to clinical practice.J Hepatol. 2016; 65: 1006-1016
- Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.Aliment Pharmacol Ther. 2015; 41: 1271-1280
- Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.J Hepatol. 2016; 65: 570-578
- Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity.Radiology. 2017; 283: 418-428
- Association between obesity and discordance in fibrosis stage determination by magnetic resonance vs transient elastography in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2018; 16: 1974-1982.e7
- Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: non-invasive tests are enough.Liver Int. 2018; 38: 67-70
- Screening for liver fibrosis in the general population: a call to action.Lancet Gastroenterol Hepatol. 2016; 1: 256-260
- Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups.Dig Liver Dis. 2015; 47: 997-1006
- Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.PLoS One. 2012; 7: e38322
Article info
Publication history
Published online: December 23, 2019
Footnotes
Support: No specific funding source.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
